Science

Neoadjuvant and Adjuvant Osimertinib in Stage IA to IIIA, EGFR-Mutant NSCLC

Photo: depositphotos.com

May 12, 2025, 17:44

Neoadjuvant and Adjuvant Osimertinib in Stage IA to IIIA, EGFR-Mutant NSCLC

Elsevier Oncology shared a post on LinkedIn:

“Advancing NSCLC Treatment: Neoadjuvant and Adjuvant Osimertinib (NORA Study)

Lee et al. present groundbreaking findings on the use of Osimertinib in Stage IA to IIIA, EGFR-mutant non-small cell lung cancer (NSCLC).

Featured as the May Editor’s Choice article in the Journal of Thoracic Oncology, the NORA trial explores both neoadjuvant and adjuvant settings, offering new hope for improved patient outcomes.”

Title: Neoadjuvant and Adjuvant Osimertinib in Stage IA to IIIA, EGFR-Mutant NSCLC (NORA)

Authors: Jii Bum Lee, Su-Jin Choi, Hyo Sup Shim, Byung Jo Park, Chang Young Lee, Sumedha Sudhaman, Sharlene Velichko, Min Hee Hong, Byoung Chul Cho, Sun Min Lim.

You can read the Full Article in the Journal of Thoracic Oncology.

Osimertinib

Vun-Sin Lim, Managing Editor of the Journal of Thoracic Oncology, shared this post, adding:

“Thanks Elsevier Oncology for featuring this JTO Editor’s Choice article of the May issue!

Also read the accompanying editorial by Drs Park and Saw.”

More posts featuring Osimertinib.

Byoung Chul Cho Byung Jo Park cancer Chang Young Lee Elsevier Oncology Hyo Sup Shim Jii Bum Lee Lung cancer Min Hee Hong NORA Study NSCLC OncoDaily Oncology osimertinib Sharlene Velichko Su-Jin Choi Sumedha Sudhaman Sun Min Lim

Oncologist Near Me – Wafik S. El-Deiry: A Global Leader in Translational Oncology and Cancer Research

In Memory of Bob Marley: His Battle with Melanoma and the Importance of Early Detection

Who From Oncology is Featured in TIME100 Health 2025?

FDA Announces Aggressive Timeline to Scale 1st AI-Assisted Scientific Review Pilot

The Evolving Therapeutic Revolution in Adult Acute Lymphoblastic Leukemia